Literature DB >> 27365015

Statistical issues in pragmatic trials of behavioral economic interventions.

Andrea B Troxel1, David A Asch2, Kevin G Volpp2.   

Abstract

BACKGROUND: Randomized clinical trials provide gold-standard evidence for the efficacy of interventions, but have limitations, including highly selected populations that make inference on effectiveness difficult and a lack of ability to adapt and change midstream.
METHODS: We propose two innovations for pragmatic trial design.
RESULTS: Evidence-based evolutionary testing, a framework that allows adaptation of interventions and rapid-cycle innovation, preserves the power of randomization while acknowledging the need for adaptation and learning. An opt-out consent framework increases the fraction of the target population who participate in trials, but may lead to dampening of effect sizes.
CONCLUSION: Pragmatic trials offer numerous advantages in the evaluation of behavioral interventions in health. Statistical innovations, including evidence-based evolutionary testing and opt-out framing of consent and enrollment processes, can enhance the power of pragmatic trials and lead to more rapid progress.
© The Author(s) 2016.

Entities:  

Keywords:  Effectiveness; generalizability; innovation; opt-out consent

Mesh:

Year:  2016        PMID: 27365015      PMCID: PMC5454570          DOI: 10.1177/1740774516654862

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  22 in total

1.  Medicine. Do defaults save lives?

Authors:  Eric J Johnson; Daniel Goldstein
Journal:  Science       Date:  2003-11-21       Impact factor: 47.728

2.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy.

Authors:  Sean R Tunis; Daniel B Stryer; Carolyn M Clancy
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

3.  Automated hovering in health care--watching over the 5000 hours.

Authors:  David A Asch; Ralph W Muller; Kevin G Volpp
Journal:  N Engl J Med       Date:  2012-06-20       Impact factor: 91.245

4.  Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction.

Authors:  Gunnar H Gislason; Jeppe N Rasmussen; Steen Z Abildstrøm; Niels Gadsbøll; Pernille Buch; Jens Friberg; Søren Rasmussen; Lars Køber; Steen Stender; Mette Madsen; Christian Torp-Pedersen
Journal:  Eur Heart J       Date:  2006-01-06       Impact factor: 29.983

5.  Long-term adherence with cardiovascular drug regimens.

Authors:  Sonali P Kulkarni; Karen P Alexander; Barbara Lytle; Gerardo Heiss; Eric D Peterson
Journal:  Am Heart J       Date:  2006-01       Impact factor: 4.749

6.  Behavioral economics holds potential to deliver better results for patients, insurers, and employers.

Authors:  George Loewenstein; David A Asch; Kevin G Volpp
Journal:  Health Aff (Millwood)       Date:  2013-07       Impact factor: 6.301

7.  Full coverage for preventive medications after myocardial infarction.

Authors:  Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

8.  Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.

Authors:  David F Blackburn; Roy T Dobson; James L Blackburn; Thomas W Wilson; Mary Rose Stang; William M Semchuk
Journal:  Can J Cardiol       Date:  2005-05-01       Impact factor: 5.223

9.  Effect of Financial Incentives to Physicians, Patients, or Both on Lipid Levels: A Randomized Clinical Trial.

Authors:  David A Asch; Andrea B Troxel; Walter F Stewart; Thomas D Sequist; James B Jones; AnneMarie G Hirsch; Karen Hoffer; Jingsan Zhu; Wenli Wang; Amanda Hodlofski; Antonette B Frasch; Mark G Weiner; Darra D Finnerty; Meredith B Rosenthal; Kelsey Gangemi; Kevin G Volpp
Journal:  JAMA       Date:  2015-11-10       Impact factor: 56.272

10.  Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.

Authors:  Andrea B Troxel; David A Asch; Shivan J Mehta; Laurie Norton; Devon Taylor; Tirza A Calderon; Raymond Lim; Jingsan Zhu; Daniel M Kolansky; Brian M Drachman; Kevin G Volpp
Journal:  Am Heart J       Date:  2016-07-08       Impact factor: 5.099

View more
  3 in total

1.  Feasibility and acceptability of two incentive-based implementation strategies for mental health therapists implementing cognitive-behavioral therapy: a pilot study to inform a randomized controlled trial.

Authors:  Rinad S Beidas; Emily M Becker-Haimes; Danielle R Adams; Laura Skriner; Rebecca E Stewart; Courtney Benjamin Wolk; Alison M Buttenheim; Nathaniel J Williams; Patricia Inacker; Elizabeth Richey; Steven C Marcus
Journal:  Implement Sci       Date:  2017-12-15       Impact factor: 7.327

2.  Effectiveness of the e-Tabac Info Service application for smoking cessation: a pragmatic randomised controlled trial.

Authors:  Aurélie Affret; Amandine Luc; Cédric Baumann; Pierre Bergman; Anne-Laurence Le Faou; Anne Pasquereau; Pierre Arwidson; François Alla; Linda Cambon
Journal:  BMJ Open       Date:  2020-10-27       Impact factor: 2.692

3.  Effectiveness of an Integrated Engagement Support System to Facilitate Patient Use of Digital Diabetes Prevention Programs: Protocol for a Randomized Controlled Trial.

Authors:  Katharine Lawrence; Danissa V Rodriguez; Dawn M Feldthouse; Donna Shelley; Jonathan L Yu; Hayley M Belli; Javier Gonzalez; Sumaiya Tasneem; Jerlisa Fontaine; Lisa L Groom; Son Luu; Yinxiang Wu; Kathleen M McTigue; Bonny Rockette-Wagner; Devin M Mann
Journal:  JMIR Res Protoc       Date:  2021-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.